The global metabolomics market size is estimated to be USD 1,986.5 Million in 2021 and is expected to witness a CAGR of 17.81% during the forecast period. Availability of government and private funding for metabolomics research is a key driver for the growth of the global metabolomics market. Additionally, increasing pharmaceutical and biotech R&D expenditure and growing demand for personalized medicine are some of the other drivers propelling the market growth. Nevertheless, complexity and diversity of biological samples and high cost of tools & instruments are expected to restrain the global market growth
Based on product and service, the market is segmented into bioinformatics tools and services and instruments. In 2021, the instruments segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the use of separation tools in research activities, increase in funds for research projects, and development of innovative technologies in these tools worldwide. Bioinformatics tools and services segment is expected to grow at a profitable CAGR during the forecast period. This is attributed to extensive application of these tools and services in the drug discovery process.
Based on application, the market is segmented into drug discovery, biomarker discovery, nutrigenomics, toxicology testing, functional genomics, personalized medicine, and other applications. In 2021, the biomarker discovery segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the growing effects of metabolic biomarkers to access the pathophysiological health status of patients worldwide. Drug discovery segment projected to grow at a profitable CAGR during the forecast period. This is attributed to significant technological advancements in the global market.
Based on indication, the market is segmented into neurological disorders, metabolic disorders, cancer, cardiovascular disorders, inborn errors of metabolism, and other indications. In 2021, the cancer segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the growing use of metabolomics in cancer research and increasing number of cancer patients worldwide. Metabolic disorders segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to growing occurrence of target diseases, especially among diabetes drivers of this market.
Based on end user, the market is segmented into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. In 2021, the academic and research institutes segment accounted for a significant revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the growing number of research activities in the field of metabolomics worldwide. Contract research organizations segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increase in funding to the contract research organizations to conduct metabolomics research.
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of major players , rising pre-clinical activities by CROs and pharmaceutical companies, and growing biomedical research in this region.. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the presence of a large patient group, strengthening healthcare sector, and liberalization in healthcare regulations in this region. Competitor Insights Some of the major companies in the metabolomics market are Thermo Fisher Scientific (U.S.); Agilent Technologies (U.S.); Waters Corporation (U.S.); Danaher Corporation (U.S.); Shimadzu Corporation (Japan); Bio-Rad Laboratories (U.S.); Bruker Corporation (U.S.); PerkinElmer, Inc. (U.S.); Merck KGaA (Germany); and GE Healthcare (U.S.). Investment in new technologies, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The metabolomics market report is categorized into the following segments and subsegments:
By Product and Service
Based on product and service, the market is segmented into bioinformatics tools and services and instruments. In 2021, the instruments segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the use of separation tools in research activities, increase in funds for research projects, and development of innovative technologies in these tools worldwide. Bioinformatics tools and services segment is expected to grow at a profitable CAGR during the forecast period. This is attributed to extensive application of these tools and services in the drug discovery process.
By Application
Based on application, the market is segmented into drug discovery, biomarker discovery, nutrigenomics, toxicology testing, functional genomics, personalized medicine, and other applications. In 2021, the biomarker discovery segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the growing effects of metabolic biomarkers to access the pathophysiological health status of patients worldwide. Drug discovery segment projected to grow at a profitable CAGR during the forecast period. This is attributed to significant technological advancements in the global market.
By Indication
Based on indication, the market is segmented into neurological disorders, metabolic disorders, cancer, cardiovascular disorders, inborn errors of metabolism, and other indications. In 2021, the cancer segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the growing use of metabolomics in cancer research and increasing number of cancer patients worldwide. Metabolic disorders segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to growing occurrence of target diseases, especially among diabetes drivers of this market.
By End User
Based on end user, the market is segmented into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. In 2021, the academic and research institutes segment accounted for a significant revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the growing number of research activities in the field of metabolomics worldwide. Contract research organizations segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increase in funding to the contract research organizations to conduct metabolomics research.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of major players , rising pre-clinical activities by CROs and pharmaceutical companies, and growing biomedical research in this region.. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the presence of a large patient group, strengthening healthcare sector, and liberalization in healthcare regulations in this region. Competitor Insights Some of the major companies in the metabolomics market are Thermo Fisher Scientific (U.S.); Agilent Technologies (U.S.); Waters Corporation (U.S.); Danaher Corporation (U.S.); Shimadzu Corporation (Japan); Bio-Rad Laboratories (U.S.); Bruker Corporation (U.S.); PerkinElmer, Inc. (U.S.); Merck KGaA (Germany); and GE Healthcare (U.S.). Investment in new technologies, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The metabolomics market report is categorized into the following segments and subsegments:
Metabolomics Market, By Product and Service (Revenue, 2021-2029, USD Million)
Bioinformatics Tools & Services
Bioinformatics Services- Bioinformatics Tools & Databases
Instruments
Separation Tools- High-Performance Liquid Chromatography
- Gas Chromatography
- Ultra-Performance Liquid Chromatography
- Capillary Electrophoresis
- Detection Tools
- Mass Spectrometry
- Nuclear Magnetic Resonance Spectroscopy
- Surface-Based Mass Analysis
Metabolomics Market, By Application (Revenue, 2021-2029, USD Million)
- Drug Discovery
- Biomarker Discovery
- Nutrigenomics
- Toxicology Testing
- Functional Genomics
- Personalized Medicine
- Other Applications
Metabolomics Market, By Indication (Revenue, 2021-2029, USD Million)
- Neurological Disorders
- Metabolic Disorders
- Cancer
- Cardiovascular Disorders
- Inborn Errors of Metabolism
- Others
Metabolomics Market, By End User (Revenue, 2021-2029, USD Million)
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations (CROS)
- Others
Metabolomics Market, By Region (Revenue, 2021-2029, USD Million)
North America
U.S.- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
South Africa- Saudi Arabia
- Rest of MEA
Table of Contents
1. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Metabolomics Market
7. Market Analysis by Product & Service
8. Market Analysis by Application
9. Market Analysis by Indication
10. Market Analysis by End user
11. Regional Market Analysis
12. North America Metabolomics Market
11. Europe Metabolomics Market
12. Asia PacificMetabolomics Market
13. Latin America Metabolomics Market
14. MEAMetabolomics Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Thermo Fisher Scientific (U.S.)
- Agilent Technologies (U.S.)
- Waters Corporation (U.S.)
- Danaher Corporation (U.S.)
- Shimadzu Corporation (Japan)
- Bio-Rad Laboratories (U.S.)
- Bruker Corporation (U.S.)
- PerkinElmer Inc. (U.S.)
- Merck KGaA (Germany)
- GE Healthcare (U.S.)
